Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:137 |
|---|---|
| Enthalten in: |
European annals of otorhinolaryngology, head and neck diseases - 137(2020), 4 vom: 27. Sept., Seite 315-317 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Herman, P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 10.09.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anorl.2020.04.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310629683 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310629683 | ||
| 003 | DE-627 | ||
| 005 | 20231225140514.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anorl.2020.04.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310629683 | ||
| 035 | |a (NLM)32482571 | ||
| 035 | |a (PII)S1879-7296(20)30104-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Herman, P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.09.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections | ||
| 650 | 4 | |a Consensus Development Conference | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Anosmia | |
| 650 | 4 | |a Bell's palsy | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Prednisone | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Sudden hearing loss | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Vincent, C |e verfasserin |4 aut | |
| 700 | 1 | |a Parietti Winkler, C |e verfasserin |4 aut | |
| 700 | 1 | |a Loundon, N |e verfasserin |4 aut | |
| 700 | 1 | |a Couloigner, V |e verfasserin |4 aut | |
| 700 | 1 | |a Tankere, F |e verfasserin |4 aut | |
| 700 | 1 | |a Tringali, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gallet, P |e verfasserin |4 aut | |
| 700 | 1 | |a Papon, J-F |e verfasserin |4 aut | |
| 700 | 1 | |a Montava, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lavieille, J-P |e verfasserin |4 aut | |
| 700 | 1 | |a Charpiot, A |e verfasserin |4 aut | |
| 700 | 1 | |a Schmerber, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European annals of otorhinolaryngology, head and neck diseases |d 2010 |g 137(2020), 4 vom: 27. Sept., Seite 315-317 |w (DE-627)NLM201398648 |x 1879-730X |7 nnns |
| 773 | 1 | 8 | |g volume:137 |g year:2020 |g number:4 |g day:27 |g month:09 |g pages:315-317 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anorl.2020.04.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 137 |j 2020 |e 4 |b 27 |c 09 |h 315-317 | ||